Stock MEIP MEI PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.86 USD -1.38% Intraday chart for MEI Pharma, Inc. -7.74% -50.69%
May. 09 MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Apr. 11 MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
BU
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
BU
MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab in Relapsed Metastatic Colorectal Cancer Patients
AQ
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
BU
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
BU
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data
CI
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
CI
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
BU
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
BU
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
CI
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
BU
Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating
MT
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
BU
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
BU
MEI Pharma : Change in Certifying Accountants - Form 8-K
PU
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
BU
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
BU
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MEIP Stock
  4. News MEI Pharma, Inc.